A phase III clinical trial of adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients nadim-adjuvant: New adjuvant trial of chemotherapy versus chemoimmunotherapy.

Virginia Calvo,Manuel Domine,Ivana Sullivan,Jose-Luis Gonzalez-Larriba,Ana Laura Ortega,R. Bernabe,Maria Ángeles Sala,B. Campos,Javier de Castro,Paloma Martín Martorell,Joaquim Bosch-Barrera,X. Mielgo,Laia Vilà,Joaquín Casal,Silver Ros,Maite Martínez Aguillo,A. Padilla,Sergio Sandiego,Jonathan Aires Machado,Mariano Provencio-Pulla

A phase III clinical trial of adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients nadim-adjuvant: New adjuvant trial of chemotherapy versus chemoimmunotherapy.

2021

TPS8581Background: The results of current studies are considered acceptable evidence to support the hypothesis of efficacy of the proposed combination of immunotherapy with chemotherapy (CT-IO) in ...

Keywords:

Medicine
Internal medicine
Chemoimmunotherapy
non-small cell lung cancer (NSCLC)
Oncology
Chemotherapy
adjuvant chemotherapy
Adjuvant
Clinical trial
stage ib
Immunotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations